•  
  •  
  •  
  •  

2025-12-02 18:36:43

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Hexaware Celebrates 22 Wins at 2025 MarCom Awards, Scoring in Every Entered Category
  • R.P.P Infra Projects Ltd wins new orders worth Rs. 25.99 Crores
  • IRFC returns to the External Commercial Borrowing market after more than three years for raising JPY equivalent USD 300 million
  • Neetu Yoshi Ltd receives orders worth Rs. 18.63 crores
  • SUGS Lloyd Ltd receives NOA form Punjab State Power Corporation Ltd

Keywords Selected:  Biologics

Stock Report

  • Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World
  • Biocon Biologics' Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated
  • Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V., a Biosimilar to Stelara®
  • Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine
  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • CuraTeQ Biologics Pvt Ltd completes Phase 3 Clinical Study for Denosumab Biosimilar
  • U.S. FDA Completes Inspection at Biocon Biologics' Facility at Biocon Campus, Bengaluru, India
  • CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
  • Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™
  • Biocon Biologics receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars
  • Biocon Biologics expands Insulin Access in Malaysia
  • Biocon Biologics receives Health Canada approval for Yesafili™
  • Biocon Biologics Collaborates with National Cancer Society Malaysia
  • Zydus enters global biologics CDMO business, plans to acquire Agenus’ U.S. manufacturing facilities to accelerate development of innovative therapies
  • Biocon Biologics and Yoshindo expand access to Ustekinumab Biosimilar in Japan
  • Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives
  • Europe (AGES, Austria) Inspection of Shilpa Biologicals Pvt Ltd
  • Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
  • CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA
  • Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
  • Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
  • CuraTeQ Biologics received Marketing Authorization for Dyrupeg™, a pegylated filgrastim biosimilar
  • Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.
  • Biocon Biologics and Civica, Inc. collaborate to expand Insulin Aspart access in the United States

Latest Post

  • Hexaware Celebrates 22 Wins at 2025 MarCom Awards, Scoring in Every Entered Category
  • R.P.P Infra Projects Ltd wins new orders worth Rs. 25.99 Crores
  • IRFC returns to the External Commercial Borrowing market after more than three years for raising JPY equivalent USD 300 million
  • Neetu Yoshi Ltd receives orders worth Rs. 18.63 crores
  • SUGS Lloyd Ltd receives NOA form Punjab State Power Corporation Ltd


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024